Curt Herberts III Sells 15,000 Shares of Sangamo Therapeutics, Inc. (SGMO) Stock
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt Herberts III sold 15,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $15.25, for a total value of $228,750.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Sangamo Therapeutics, Inc. (NASDAQ SGMO) traded up 0.32% during trading on Tuesday, reaching $15.90. The company had a trading volume of 961,240 shares. The firm’s market capitalization is $1.33 billion. The firm has a 50-day moving average of $13.65 and a 200 day moving average of $8.88. Sangamo Therapeutics, Inc. has a 1-year low of $2.65 and a 1-year high of $17.06.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. The business had revenue of $8.30 million during the quarter, compared to the consensus estimate of $5.82 million. During the same quarter in the prior year, the firm earned ($0.38) earnings per share. The business’s quarterly revenue was up 124.3% compared to the same quarter last year. Analysts expect that Sangamo Therapeutics, Inc. will post ($0.82) earnings per share for the current year.
A number of equities analysts have recently weighed in on the company. ValuEngine raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Piper Jaffray Companies set a $8.00 price objective on Sangamo Therapeutics and gave the company a “hold” rating in a research report on Thursday, August 10th. BidaskClub downgraded Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Friday, August 18th. Finally, Jefferies Group LLC restated a “buy” rating and set a $17.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $14.40.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Blair William & Co. IL increased its holdings in Sangamo Therapeutics by 4.3% in the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 500 shares in the last quarter. Aperio Group LLC acquired a new stake in shares of Sangamo Therapeutics in the second quarter valued at approximately $108,000. Principal Financial Group Inc. grew its position in shares of Sangamo Therapeutics by 6.8% in the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 832 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in shares of Sangamo Therapeutics in the second quarter valued at approximately $124,000. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Sangamo Therapeutics in the second quarter valued at approximately $126,000. 63.43% of the stock is owned by hedge funds and other institutional investors.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.